KATINA EDWARDS: Open Payments
NPI 1568810117 · IRVINE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,919 in 90 payments from 13 companies in 2025. Trend: 2023 $0 · 2024 $337 · 2025 $1,919
Food & beverage: $1,919
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 20 | $520 |
| Teva Pharmaceuticals USA, Inc. | 21 | $360 |
| Otsuka America Pharmaceutical, Inc. | 13 | $267 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $186 |
| Janssen Pharmaceuticals, Inc | 7 | $156 |
| E.R. Squibb & Sons, L.L.C. | 6 | $137 |
| Vanda Pharmaceuticals Inc. | 5 | $109 |
| Axsome Therapeutics, Inc. | 3 | $62 |
| ABBVIE INC. | 2 | $36 |
| Lundbeck LLC | 1 | $32 |
Products named: INGREZZA, REXULTI, UZEDY, CAPLYTA, AUSTEDO XR, COBENFY, ABILIFY ASIMTUFII, SPRAVATO.
Industry payments across CA — which companies pay providers there.
